Efficacy end points for the DASISION and ENESTnd trials
| . | DASISION13 . | ENESTnd14 . | |||
|---|---|---|---|---|---|
| Imatinib . | Dasatinib . | Imatinib . | Nilotinib . | ||
| 400 mg daily (n = 260) . | 100 mg daily (n = 259) . | 400 mg daily (n = 283) . | 300 mg twice daily (n = 282) . | 400 mg twice daily (n = 281) . | |
| Cumulative MMR at 5 y, % | 64 | 76 | 60 | 77 | 77 |
| MR4.5 at 5 y, % | 33 | 42 | 31 | 54 | 52 |
| Progression to AP/BC, % | 7 | 5 | 7 | 4 | 3 |
| 5-y OS (ITT), % | 90 | 91 | 92 | 94 | 96 |
| 5-y PFS, % | 86 | 85 | 91 | 92 | 96 |
| . | DASISION13 . | ENESTnd14 . | |||
|---|---|---|---|---|---|
| Imatinib . | Dasatinib . | Imatinib . | Nilotinib . | ||
| 400 mg daily (n = 260) . | 100 mg daily (n = 259) . | 400 mg daily (n = 283) . | 300 mg twice daily (n = 282) . | 400 mg twice daily (n = 281) . | |
| Cumulative MMR at 5 y, % | 64 | 76 | 60 | 77 | 77 |
| MR4.5 at 5 y, % | 33 | 42 | 31 | 54 | 52 |
| Progression to AP/BC, % | 7 | 5 | 7 | 4 | 3 |
| 5-y OS (ITT), % | 90 | 91 | 92 | 94 | 96 |
| 5-y PFS, % | 86 | 85 | 91 | 92 | 96 |
AP, accelerated phase; BC, blast crisis; ITT, intention to treat.